{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:01:04Z","timestamp":1792591264321,"version":"4.5.0"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81660297"],"award-info":[{"award-number":["81660297"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2022MS03019"],"award-info":[{"award-number":["2022MS03019"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004763","name":"Natural Science Foundation of Inner Mongolia","doi-asserted-by":"publisher","award":["81660297"],"award-info":[{"award-number":["81660297"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004763","name":"Natural Science Foundation of Inner Mongolia","doi-asserted-by":"publisher","award":["2022MS03019"],"award-info":[{"award-number":["2022MS03019"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>B-cell lymphoma is a group of malignant proliferative diseases originating from lymphoid tissue with different clinical manifestations and biological characteristics. It can occur in any part of the body, accounting for more than 80% of all lymphomas. The present study aimed to construct bispecific single-domain antibodies against CD20 and CD3 and to evaluate their function in killing tumor cells in vitro. A Bactrian camel was immunized with a human CD20 extracellular peptide, and the VHH gene was cloned and ligated into a phagemid vector to construct the phage antibody display library. A phage antibody library with a size of 1.2 \u00d7 108 was successfully constructed, and the VHH gene insertion rate was 91.7%. Ninety-two individual clones were randomly picked and screened by phage ELISA. Six strains with the high binding ability to human CD20 were named 11, 30, 71, 72, 83, and 92, and induced expression and purification were performed to obtain soluble CD20 single-domain antibodies. The obtained single-domain antibodies could specifically bind to human CD20 polypeptide and cell surface-expressed CD20 molecules in ELISA, Western blot, and cell immunofluorescence assays. The anti-CD20\/CD3 bispecific nanobody (BsNb) was successfully constructed by fusing the anti-CD20 VHH gene with the anti-CD3 VHH and the bispecific single-domain antibody was expressed, purified, and validated. Anti-CD20\/CD3 BsNb can specifically bind CD20 molecules on the surface of human lymphoma Raji cells and CD3 molecules on the surface of T cells in flow cytometry analysis and effectively mediate peripheral blood mononuclear cells (PBMCs) target Raji cells with a killing efficiency of up to 30.4%, as measured by the lactate dehydrogenase (LDH) method. The release of hIFN-\u03b3 from PBMCs during incubation with anti-CD20\/CD3 BsNb was significantly higher than that of the control group (p &lt; 0.01). The anti-CD20\/CD3 BsNb could maintain 80% binding activity after incubation with human serum at 37 \u00b0C for 48 h. These results indicated the strong antitumor effect of the constructed anti-CD20\/CD3 BsNb and laid the foundation for the further development of antitumor agents and the clinical application of anti-CD20\/CD3 BsNb.<\/jats:p>","DOI":"10.3390\/vaccines10081335","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T22:53:30Z","timestamp":1660776810000},"page":"1335","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells"],"prefix":"10.3390","volume":"10","author":[{"given":"Yanlong","family":"Liu","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, Inner Mongolia Agricultural University, Huhhot 010010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Ao","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Inner Mongolia Agricultural University, Huhhot 010010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxiang","family":"Bao","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Inner Mongolia Agricultural University, Huhhot 010010, China"},{"name":"Key Laboratory of Clinical Diagnosis and Treatment Techniques for Animal Disease, Ministry of Agriculture and Rural Affairs (LDTA), Huhhot 010010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cheng","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Inner Mongolia Agricultural University, Huhhot 010010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Hao","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Inner Mongolia Agricultural University, Huhhot 010010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Inner Mongolia Agricultural University, Huhhot 010010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Fu","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Inner Mongolia Agricultural University, Huhhot 010010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Xu","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Inner Mongolia Agricultural University, Huhhot 010010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyao","family":"Wu","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Inner Mongolia Agricultural University, Huhhot 010010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Howlader, N., Noone, A.M., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., Altekruse, S.F., Kosary, C.L., Ruhl, J., and Tatalovich, Z. (2012). SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations)."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7748\/cnp2014.02.13.1.31.e1042","article-title":"An overview of non-Hodgkin\u2019s lymphoma","volume":"13","author":"King","year":"2014","journal-title":"Cancer Nurs. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: An \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0378-1119(00)00598-9","article-title":"Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor","volume":"264","author":"Ishibashi","year":"2001","journal-title":"Gene"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clim.2016.08.011","article-title":"Anti-CD20 antibody treatment of non-Hodgkin lymphomas","volume":"172","author":"Engelhard","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: A regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol. Today"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4161\/mabs.24108","article-title":"Response to: Monoclonal antibodies targeting CD20","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2217\/fon.12.157","article-title":"Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia","volume":"9","author":"Robak","year":"2013","journal-title":"Future Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1038\/s41598-020-68470-9","article-title":"Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment","volume":"10","author":"Mizuno","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/asheducation-2007.1.233","article-title":"Monoclonal antibodies for B-cell lymphomas: Rituximab and beyond","volume":"2007","author":"Bello","year":"2007","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1134\/S0026893311010134","article-title":"\u201cCamel nanoantibody\u201d is an efficient tool for research, diagnostics and therapy","volume":"45","author":"Tillib","year":"2011","journal-title":"Mol. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3389\/fimmu.2017.01589","article-title":"Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook","volume":"8","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/febs.15515","article-title":"A guide to: Generation and design of nanobodies","volume":"288","author":"Muyldermans","year":"2021","journal-title":"Febs J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"15130","DOI":"10.1038\/s41598-017-15417-2","article-title":"A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells","volume":"7","author":"Balhuizen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"632687","DOI":"10.3389\/fimmu.2021.632687","article-title":"Immunogenicity Risk Profile of Nanobodies","volume":"12","author":"Ackaert","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.132.3441.1770","article-title":"Properties of the major component of a peptic digest of rabbit antibody","volume":"132","author":"Nisonoff","year":"1960","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wang, Q., Chen, Y., Park, J., Liu, X., Hu, Y., Wang, T., McFarland, K., and Betenbaugh, M.J. (2019). Design and Production of Bispecific Antibodies. Antibodies, 8.","DOI":"10.3390\/antib8030043"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.drudis.2017.12.004","article-title":"Corrigendum to \u201cBispecific antibodies\u201d [Drug Discov. Today 20 (July (7)) (2015) 838-847]","volume":"24","author":"Kontermann","year":"2019","journal-title":"Drug Discov. Today."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mohan, N., Luo, X., Shen, Y., Olson, Z., Agrawal, A., Endo, Y., Rotstein, D.S., Pelosof, L.C., and Wu, W.J. (2021). A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action. Cancers, 13.","DOI":"10.3390\/cancers13051027"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","article-title":"Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates","volume":"6","author":"Yu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.HS9.0000561752.46264.f3","article-title":"Emerging clinical activity of REGN1979, an anti-CD20 X ANTI-CD3 bispecific antibody (AB), in patients (PTS) with relapsed\/refractory (R\/R) B-cell non-hodgkin lymphoma (B-NHL): S868","volume":"3","author":"Bannerji","year":"2019","journal-title":"HemaSphere"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-61779-968-6_2","article-title":"Introduction to heavy chain antibodies and derived Nanobodies","volume":"911","author":"Vincke","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: Successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11530960-000000000-00000","article-title":"Bispecific antibodies for cancer immunotherapy: Current perspectives","volume":"24","author":"Kontermann","year":"2010","journal-title":"BioDrugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/mabs.1.6.10015","article-title":"Bispecific antibodies for cancer therapy: The light at the end of the tunnel?","volume":"1","author":"Chames","year":"2009","journal-title":"MAbs"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Yang, F., Wen, W., and Qin, W. (2016). Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18010048"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Salvaris, R., and Ong, J. (2021). Gregory GP. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050355"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific antibody based therapeutics: Strengths and challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1479-5876-12-191","article-title":"Ipilimumab augments antitumor activity of bispecific antibody-armed T cells","volume":"12","author":"Yano","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/15258160151134944","article-title":"Use of anti-CD3 x anti-HER2\/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2\/neu+ tumors","volume":"10","author":"Sen","year":"2001","journal-title":"J. Hematother. Stem Cell Res."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1335\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:11:16Z","timestamp":1760141476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["vaccines10081335"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10081335","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]}}}